Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

在PVRI大会上展示的信息基于Gossamer Bio的新闻稿。公司将继续研究seralutinib的有效性和安全性，以满足肺动脉高压患者未得到满足的医疗需求。与所有临床研究一样，这些发现将在科学界接受进一步的审查和验证。

A-list guests like Laverne Cox, Tiffany Haddish, Julianne Hough, Katie Holmes and Whoopi Goldberg were seated in the front ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate ...

The Gossamer-1 project is concerned with the development and establishment of a space-qualified technology for the deployment of ultra-light, large foil structures in space. The core technologies are ...

Gossamer Bio (GOSS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Gossamer Bio (GOSS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 24. Analyst Joseph ...

Earnings Estimate Revisions for Gossamer Bio This biopharmaceutical company is expected to earn -$0.28 per share for the fiscal year ending December 2024, which represents a year-over-year change ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated price ...